Anti-Parkinsonian agents have anti-amyloidogenic activity for Alzheimer's β-amyloid fibrils in vitro

Neurochemistry International

Volumn 48, Issue 4, 2006, Pages 275-285

  Ono, Kenjiro ^a   Hasegawa, Kazuhiro ^b,c   Naiki, Hironobu ^b,c   Yamada, Masahito ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b UNIVERSITY OF FUKUI   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Amyloid fibrils; Alzheimer's disease; Anti Parkinsonian agents; Electron microscopy; Thioflavin T

Indexed keywords

ANTIPARKINSON AGENT; BROMOCRIPTINE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR; MUSCARINIC RECEPTOR BLOCKING AGENT; NORDIHYDROGUAIARETIC ACID; PERGOLIDE; SELEGILINE; THIOFLAVINE; TRIHEXYPHENIDYL;

ALZHEIMER DISEASE; AMYLOIDOSIS; ARTICLE; CONCENTRATION RESPONSE; DOSE RESPONSE; ELECTRON MICROSCOPY; FLUORESCENCE SPECTROSCOPY; NEUROPROTECTION; PARKINSON DISEASE; PRIORITY JOURNAL;

AMYLOID BETA-PROTEIN; ANTIPARKINSON AGENTS; HUMANS; KINETICS; MICROSCOPY, ELECTRON; SPECTROMETRY, FLUORESCENCE;

PARKINSONIA;

EID: 31744447521     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2005.11.001     Document Type: Article

References (40)

1. M.M. Bradford A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding Anal. Biochem. 72 1976 248 254
2. K.K. Chung, V.L. Dawson, and T.M. Dawson New insights into Parkinson's disease J. Neurol. 250 Suppl. 3 2003 III15 III24
3. G. Forloni, L. Colombo, L. Girola, F. Tagliavini, and M. Salmona Anti-amyloidogenic activity of tetracyclines: studies in vitro FEBS Lett. 487 2001 404 407
4. M. Gómez-Vargas, S. Nishibayashi-Asanuma, M. Asanuma, Y. Kondo, E. Iwata, and N. Ogawa Pergolide scavenges both hydroxyl and nitric oxide free radicals in vitro and inhibits lipid peroxidation in different regions of the rat brain Brain Res. 790 1998 202 208
5. Y. Goodman, M.R. Steiner, S.M. Steiner, and M.P. Mattson Nordihydroguaiaretic acid protects hippocampal neurons against amyloid beta-peptide toxicity, and attenuates free radical and calcium accumulation Brain Res. 654 1994 171 176
6. L.A. Hansen, and W. Samuel Criteria for Alzheimer's disease and the nosology of dementia with Lewy bodies Neurology 48 1997 126 132
7. J.D. Harper, S.S. Wong, C.M. Lieber, and P.T. Lansbury Assembly of A beta amyloid protofibrils: an in vitro model for a possible early event in Alzheimer's disease Biochemistry 38 1999 8972 8980
8. K. Hasegawa, K. Ono, M. Yamada, and H. Naiki Kinetic modeling and determination of reaction constants of Alzheimer's β-amyloid fibril extension and dissociation using surface plasmon resonance Biochemistry 41 2002 13489 13498
9. K. Hasegawa, I. Yamaguchi, S. Omata, F. Gejyo, and H. Naiki Interaction between A beta(1-42) and A beta(1-40) in Alzheimer's beta-amyloid fibril formation in vitro Biochemistry 38 1999 15514 15521
10. J.T. Jarrett, and P.T. Lansbury Jr. Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell 73 1993 1055 1058
11. T. Kihara, S. Shimohama, H. Sawada, J. Kimura, T. Kume, H. Kochiyama, T. Maeda, and A. Akaike Nicotinic receptor stimulation protects neurons against beta-amyloid toxicity Ann. Neurol. 42 1997 159 163
12. J. Li, M. Zhu, A.B. Manning-Bog, D.A. Di Monte, and A.L. Fink Dopamine and l-Dopa disaggregate amyloid fibrils: implications for Parkinson's and Alzheimer's disease FASEB J. 18 2004 962 964
13. W. Linert, M.H. Bridge, M. Huber, K.B. Bjugstad, S. Grossman, and G.W. Arendash In vitro and in vivo studies investigating possible antioxidant actions of nicotine: relevance to Parkinson's and Alzheimer's diseases Biochim. Biophys. Acta 1454 1999 143 152
14. A. Mangoni, M.P. Grassi, L. Frattola, R. Piolti, S. Bassi, A. Motta, A. Marcone, and S. Smirne Effects of a MAO-B inhibitor in the treatment of Alzheimer disease Eur. Neurol. 31 1991 100 107
15. E.G. McGeer, and P.L. McGeer Brain inflammation in Alzheimer disease and the therapeutic implications Curr. Pharm. Des. 5 1999 821 836
16. I.G. McKeith Spectrum of Parkinson's disease, Parkinson's dementia, and Lewy body dementia Neurol. Clin. 18 2000 865 902
17. M.C. Morris, D.A. Evans, J.L. Bienias, C.C. Tangney, and R.S. Wilson Vitamin E and cognitive decline in older persons Arch. Neurol. 59 2002 1125 1132
18. H. Naiki, F. Gejyo, and K. Nakakuki Concentration-dependent inhibitory effects of apolipoprotein E on Alzheimer's beta-amyloid fibril formation in vitro Biochemistry 36 1997 6243 6250
19. H. Naiki, K. Hasegawa, I. Yamaguchi, H. Nakamura, F. Gejyo, and K. Nakakuki Apolipoprotein E and antioxidants have different mechanisms of inhibiting Alzheimer's beta-amyloid fibril formation in vitro Biochemistry 37 1998 17882 17889
20. H. Naiki, and K. Nakakuki First-order kinetic model of Alzheimer's beta-amyloid fibril extension in vitro Lab. Invest. 74 1996 374 383
21. S. Nakai, and F. Yoneda A theoretical investigation of (-)-deprenyl (selegiline) as a radical scavenger Theor. Chem. Acc. 104 2000 398 406
22. M.R. Nichols, M.A. Moss, D.K. Reed, W.L. Lin, R. Mukhopadhyay, J.H. Hoh, and T.L. Rosenberry Growth of beta-amyloid(1-40) protofibrils by monomer elongation and lateral association. Characterization of distinct products by light scattering and atomic force microscopy Biochemistry 41 2002 6115 6127
23. N. Ogawa, K. Tanaka, M. Asanuma, M. Kawai, T. Masumizu, M. Kohno, and A. Mori Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro Brain Res. 657 1994 207 213
24. K. Ono, K. Hasegawa, M. Yamada, and H. Naiki Nicotine breaks down preformed Alzheimer's beta-amyloid fibrils in vitro Biol. Psychiatry 52 2002 880 886
25. K. Ono, K. Hasegawa, Y. Yoshiike, A. Takashima, M. Yamada, and H. Naiki Nordihydroguaiaretic acid potently breaks down pre-formed Alzheimer's beta-amyloid fibrils in vitro J. Neurochem. 81 2002 434 440
26. K. Ono, Y. Yoshiike, A. Takashima, K. Hasegawa, H. Naiki, and M. Yamada Potent anti-amyloidogenic and fibril-destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimer's disease J. Neurochem. 87 2003 172 181
27. K. Ono, K. Hasegawa, H. Naiki, and M. Yamada Curcumin has potent anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro J. Neurosci. Res. 75 2004 742 750
28. K. Ono, K. Hasegawa, H. Naiki, and M. Yamada Anti-amyloidogenic activity of tannic acid and its activity to destabilize Alzheimer's beta-amyloid fibrils in vitro Biochim. Biophys. Acta 1690 2004 193 202
29. K. Ono, Y. Yoshiike, A. Takashima, K. Hasegawa, H. Naiki, and M. Yamada Vitamin A exhibits potent antiamyloidogenic and fibril-destabilizing effects in vitro Exp. Neurol. 189 2004 380 392
30. E.K. Perry, L. Kilford, A.J. Lees, D.J. Burn, and R.H. Perry Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs Ann. Neurol. 54 2003 235 238
31. D. Pratico, and N. Delanty Oxidative injury in diseases of the central nervous system: focus on Alzheimer's disease Am. J. Med. 109 2000 577 585
32. M. Sano, C. Ernesto, R.G. Thomas, M.R. Klauber, K. Schafer, M. Grundman, P. Woodbury, J. Growdon, C.W. Cotman, E. Pfeiffer, L.S. Schneider, and L.J. Thal A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's disease cooperative study N. Engl. J. Med. 336 1997 1216 1222
33. D. Schenk, R. Barbour, W. Dunn, G. Gordon, H. Grajeda, T. Guido, K. Hu, J. Huang, K. Johnson-Wood, K. Khan, D. Kholodenko, M. Lee, Z. Liao, I. Lieberburg, R. Motter, L. Mutter, F. Soriano, G. Shopp, N. Vasquez, C. Vandevert, S. Walker, M. Wogulis, T. Yednock, D. Games, and P. Seubert Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse Nature 400 1999 173 177
34. D.J. Selkoe Alzheimer's disease: genes, proteins, and therapy Physiol. Rev. 81 2001 741 766
35. J.P. Spencer, A. Jenner, J. Butler, O.I. Aruoma, D.T. Dexter, P. Jenner, and B. Halliwell Evaluation of the pro-oxidant and antioxidant actions of l-Dopa and dopamine in vitro: implications for Parkinson's disease Free Radic. Res. 24 1996 95 105
36. R. Subramaniam, T. Koppal, M. Green, S. Yatin, B. Jordan, J. Drake, and D.A. Butterfield The free radical antioxidant Vitamin E protects cortical synaptosomal membranes from amyloid beta-peptide (25-35) toxicity but not from hydroxynonenal toxicity: relevance to the free radical hypothesis of Alzheimer's disease Neurochem. Res. 23 1998 1403 1410
37. T. Tomiyama, A. Shoji, K. Kataoka, Y. Suwa, S. Asano, H. Kaneko, and N. Endo Inhibition of amyloid beta protein aggregation and neurotoxicity by rifampicin. Its possible function as a hydroxyl radical scavenger J. Biol. Chem. 271 1996 6839 6844
38. R.M. Wu, C.C. Chiueh, A. Pert, and D.L. Murphy Apparent antioxidant effect of l-deprenyl on hydroxyl radical formation and nigral injury elicited by MPP+ in vivo Eur. J. Pharmacol. 243 1993 241 247
39. G.C. Yen, and C.L. Hsieh Antioxidant effects of dopamine and related compounds Biosci. Biotechnol. Biochem. 61 1997 1646 1649
40. H. Zeng, Y. Zhang, L.-J. Peng, H. Shao, N.K. Menon, J. Yang, A.R. Salomon, R.P. Freidland, and M.G. Zagorski Nicotine and amyloid formation Biol. Psychiatry 49 2001 248 257